Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Luye Pharma’s Shandong Boan Partners with Shanghai Pharmaceutical for Biologics Manufacturing
China-based Luye Pharma Group (HKG: 2186) has announced that its controlling subsidiary, Shandong Boan Biotechnology...
Staidson’s STSP-0601 Receives Clinical Trial Approval for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...
Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion
Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has...
Rainmed Medical’s caFFR System Receives TGA Approval for Coronary Disease Diagnosis
China-based Rainmed Medical Limited has announced that it has received market approval from Australia’s Therapeutic...
NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development
NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round...
Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New...
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...
Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...
Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...
Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...
Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...
Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics
Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...
Biosyngen to Establish Cell Therapy GMP Facility in Singapore
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...
Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges
China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...
Parexel Opens Clinical Study Supply Chain Center in Suzhou
US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...
Arctic Vision Enrolls First Patient in Phase III Study for ARVN002
China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...